Join to View Full Profile
3592 W 9000 SSte 200West Jordan, UT 84088
Phone+1 801-562-8732
Fax+1 801-267-5633
Dr. Call is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2005 - 2008- University of ColoradoResidency, Internal Medicine, 2001 - 2004
- University of Colorado School of Medicine Anschutz Medical CampusClass of 2001
Certifications & Licensure
UT State Medical License 2012 - 2026
MI State Medical License 2008 - 2015
CO State Medical License 2004 - 2013
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
- Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy Start of enrollment: 2019 Dec 15
- PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) Start of enrollment: 2023 Mar 15
Roles: Contact
Publications & Presentations
PubMed
- First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.Nehal J Lakhani, Daphne Stewart, Debra L Richardson, Lauren E Dockery, Linda Van Le
Journal for Immunotherapy of Cancer. 2025-01-11 - 27 citationsARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.Melissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, Justin Call, Paul R Kunk
Clinical Cancer Research. 2022-06-13 - 78 citationsParsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S. Wertheim, William Jeffery Edenfield
Blood. 2019-04-18
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
